OTCMKTS:IPSEY Ipsen (IPSEY) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free IPSEY Stock Alerts $29.88 +0.47 (+1.60%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$29.80▼$29.9550-Day Range$27.50▼$29.8852-Week Range$26.97▼$34.34Volume520 shsAverage Volume1,240 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield0.77%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort Interest Get Ipsen alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Ipsen Stock (OTCMKTS:IPSEY)Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.Read More IPSEY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPSEY Stock News HeadlinesFebruary 15, 2024 | globenewswire.comIpsen S.A. publishes its 2023 Consolidated Financial StatementsFebruary 14, 2024 | financialpost.comIpsen's Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDAMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 13, 2024 | finance.yahoo.comIpsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDAFebruary 13, 2024 | msn.comIpsen gets FDA approval for pancreatic cancer drug regimenFebruary 8, 2024 | marketwatch.comIpsen Shares Fall After Forecast of Lower MarginFebruary 8, 2024 | markets.businessinsider.comBuilding on solid FY 2023 results, Ipsen anticipates four launches in 2024February 8, 2024 | markets.businessinsider.comIpsen FY23 Profit Flat, Sales Rise; Sees Growth In FY24, Backs Mid-term ViewMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 8, 2024 | msn.comIpsen S.A. Non-GAAP EPS of €9.15, revenue of €3.13B; initiates FY24 outlookFebruary 6, 2024 | finance.yahoo.comIpsen - Monthly information relative to the total number of voting rights and shares composing the share capitalJanuary 31, 2024 | markets.businessinsider.comBiotech Stocks Facing FDA Decision In February 2024January 22, 2024 | finanznachrichten.deIpsen Pharma: Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024January 22, 2024 | finance.yahoo.comLatest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024December 7, 2023 | markets.businessinsider.comIpsen : FDA Grants Priority Review To Elafibranor NDA For Rare Cholestatic Liver Disease TreatmentDecember 7, 2023 | finance.yahoo.comCapital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlookNovember 13, 2023 | markets.businessinsider.comIpsen Says Health Canada Approved Bylvay To Treat Pruritus Due To PFICNovember 13, 2023 | finance.yahoo.comIpsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)October 26, 2023 | nasdaq.comIpsen 9-month Sales UpOctober 23, 2023 | markets.businessinsider.comIpsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndromeOctober 3, 2023 | finanznachrichten.deIpsen Pharma: Ipsen updates on QM-1114 regulatory processOctober 3, 2023 | finance.yahoo.comIpsen updates on QM-1114 regulatory processSeptember 28, 2023 | fortune.comLaura IpsenSeptember 17, 2023 | msn.comIpsen celebrates 75 years of its location in Cherry ValleySeptember 1, 2023 | finance.yahoo.comIpsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle HuguetAugust 21, 2023 | msn.comExelixis lead product hits main goal in Phase 3 prostate cancer trialAugust 17, 2023 | msn.comUS FDA approves French drugmaker Ipsen's rare bone disorder drugSee More Headlines Receive IPSEY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolOTCMKTS:IPSEY CUSIPN/A CIKN/A Webwww.ipsen.com Phone(315) 833-5000Fax33-01-58-33-50-01Employees5,300Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio0.99 Sales & Book Value Annual Sales$3.58 billion Price / SalesN/A Cash Flow$3.52 per share Price / Cash Flow8.49 Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.91 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. David Loew (Age 57)MD, CEO & Director Comp: $2.41MMr. Aymeric Le Chatelier (Age 55)Executive VP & CFO Comp: $794.14kDr. Aidan Murphy Ph.D. (Age 58)Executive VP and Head of Technical Operations Mr. Craig MarksVice-President of Investor RelationsMr. Francois Garnier (Age 62)Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer Ms. Gwenan WhiteExecutive VP and Head of Communications, Public Affairs & SustainabilityMr. Regis Mulot (Age 58)Executive VP & Chief Human Resources Officer Ms. Dominique Bery (Age 53)Head of Nordics & Baltics Mr. Bartosz Bednarz D.D.S.Executive VP and Head of Global Product & Portfolio StrategyMr. Philippe Lopes-Fernandes CBOExecutive VP & Chief Business OfficerMore ExecutivesKey CompetitorsBG MedicineOTCMKTS:BGMDFluoroPharma MedicalOTCMKTS:FPMIGlobal WholeHealth PartnersOTCMKTS:GWHPHemagen DiagnosticsOTCMKTS:HMGNResponse GeneticsOTCMKTS:RGDXQView All Competitors IPSEY Stock Analysis - Frequently Asked Questions Should I buy or sell Ipsen stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IPSEY shares. View IPSEY analyst ratings or view top-rated stocks. How have IPSEY shares performed in 2024? Ipsen's stock was trading at $29.48 at the beginning of the year. Since then, IPSEY shares have increased by 1.4% and is now trading at $29.88. View the best growth stocks for 2024 here. Are investors shorting Ipsen? Ipsen saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 400 shares, a drop of 63.6% from the February 29th total of 1,100 shares. Based on an average daily trading volume, of 2,200 shares, the days-to-cover ratio is currently 0.2 days. View Ipsen's Short Interest. How often does Ipsen pay dividends? What is the dividend yield for Ipsen? Ipsen declared a dividend on Thursday, June 1st. Investors of record on Monday, June 5th will be paid a dividend of $0.2337 per share on Tuesday, June 27th. This represents a yield of 0.8%. The ex-dividend date of this dividend is Friday, June 2nd. This is a boost from the stock's previous dividend of $0.23. Read our dividend analysis for IPSEY. Is Ipsen a good dividend stock? Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.23 per share and currently has a dividend yield of 0.77%. Read our dividend analysis for IPSEY. How do I buy shares of Ipsen? Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IPSEY) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ipsen S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.